Comparison of radioimmunoprecipitation with luciferase immunoprecipitation for autoantibodies to GAD65 and IA-2β

PD Burbelo, H Hirai, AT Issa, A Kingman… - Diabetes …, 2010 - Am Diabetes Assoc
PD Burbelo, H Hirai, AT Issa, A Kingman, Å Lernmark, SA Ivarsson, AL Notkins, MJ Iadarola
Diabetes care, 2010Am Diabetes Assoc
OBJECTIVE To compare the sensitivity and specificity of luciferase immunoprecipitation
(LIPS) with radioimmunoprecipitation (RIP) for the measurement of autoantibodies to the
type 1 diabetes autoantigens glutamic acid decarboxylase 65 (GAD65) and insulinoma-
associated protein (IA)-2β. RESEARCH DESIGN AND METHODS Sera from 49 type 1
diabetic patients and 100 nondiabetic control subjects from Diabetes Antibody
Standardization Program 2007 were used to screen for autoantibodies to GAD65. An …
OBJECTIVE
To compare the sensitivity and specificity of luciferase immunoprecipitation (LIPS) with radioimmunoprecipitation (RIP) for the measurement of autoantibodies to the type 1 diabetes autoantigens glutamic acid decarboxylase 65 (GAD65) and insulinoma-associated protein (IA)-2β.
RESEARCH DESIGN AND METHODS
Sera from 49 type 1 diabetic patients and 100 nondiabetic control subjects from Diabetes Antibody Standardization Program 2007 were used to screen for autoantibodies to GAD65. An additional 200 type 1 diabetic patients and 200 nondiabetic control subjects were used to validate the GAD65 results and screen for autoantibodies to IA-2β.
RESULTS
LIPS showed equal sensitivity and specificity to RIP for detecting autoantibodies to GAD65 and IA-2β. Receiver-operating characteristic analysis revealed that the detection of autoantibodies to GAD65 and IA-2β by LIPS and RIP were not statistically different.
CONCLUSIONS
The LIPS assay does not require the use of radioisotopes or in vitro transcription/translation and is a practical alternative at the clinical level for the RIP assay.
Am Diabetes Assoc